AbbVie Inks Deal Worth $1.56 B With China's FutureGen to Develop IBD Therapy
Overview
US-based firm AbbVie and FutureGen Biopharmaceutical (Beijing) have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical development.
FG-M701
FG-M701 is a fully human monoclonal antibody targeting TL1A, a clinically validated target in IBD.
FG-M701 is uniquely engineered with potential best-in-class functional characteristics compared to first-generation TL1A antibodies with the goal to drive greater efficacy and less frequent dosing as a therapy for IBD.
Terms of the Agreement
Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialise FG-M701.
FutureGen will receive $150 million in upfront and near-term milestone payments and will be eligible to receive up to an additional $1.56 billion in clinical development, regulatory and commercial milestones, as well as tiered royalties up to low-double digits on net sales.
"The prevalence of IBD continues to increase, and many people living with ulcerative colitis and Crohn's disease do not respond to current therapies," said Jonathon Sedgwick, PhD, senior vice president and global head of discovery research, AbbVie.
Words from CEO: FutureGen Biopharmaceutical
Zhaoyu Jin, PhD, founder and chief executive officer, FutureGen Biopharmaceutical (Beijing) Co. said, "We believe that AbbVie is a great partner, with the ability to apply their expertise and global scale to realizing FG-M701's therapeutic potential and rapidly advancing this therapy for patients suffering from IBD. The collaboration with AbbVie also highlights FutureGen's ability to generate potential best-in-class product candidates with our proprietary Structure-based Targeted Evolution Platform (STEP) technology platform.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!